TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06347302

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling
Description: Two tubes will be taken, the first tube (Tube 1) for specialised lipid analysis. The second tube (Tube 2) for routine biochemical analysis

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling
Description: Two tubes will be taken, the first tube (Tube 1) for specialised lipid analysis. The second tube (Tube 2) for routine biochemical analysis

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vitreous sampling
Description: Intra-operative vitreous sampling: systematic collection of the vitreous humour during vitrectomy for vitreoretinal surgery such as retinal detachment, epiretinal membranes and macular holes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vitreous sampling
Description: Intra-operative vitreous sampling: systematic collection of the vitreous humour during vitrectomy for vitreoretinal surgery such as retinal detachment, epiretinal membranes and macular holes.
Study: NCT06524414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG4
Description: Multivalent pneumococcal conjugate vaccine
Study: NCT06347302

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sub-retinal fluid sampling
Description: Sub-retinal fluid sampling consists of collecting the sub-retinal fluid that is systematically aspirated during retinal detachment surgery in order to dry the detached retina and allow retinopexy to be performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Retinal tissue sampling
Description: cutting and aspiration of the retina using the vitreotome opposite the tear to allow access to the sub-retinal fluid.
Study: NCT06580236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B11-FC
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B11-FC
Description: Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B11-FC
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B11-FC
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B11-FC
Description: Infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum neurotoxin type A
Description: Infusion
Study: NCT06524414

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG4
Description: Multivalent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PG4
Description: Multivalent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20-valent pneumococcal conjugate vaccine (20vPnC)
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20-valent pneumococcal conjugate vaccine (20vPnC)
Description: 20-valent pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20-valent pneumococcal conjugate vaccine (20vPnC)
Description: 20-valent pneumococcal conjugate vaccine
Study: NCT06580236

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Botulinum neurotoxin type A
Description: Infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion
Study: NCT05460416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: 160mg once a day
Study: NCT06486558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU6 450 mg Tablet
Description: new 450 mg tablet test formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HU6 150 mg Capsules x 3 (Total dose = 450 mg)
Description: 150 mg capsule reference formulation (3 x 150 mg).
Study: NCT06373601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sirolimus-eluting balloon (Selution)
Description: PCI treatment with DCB, in particular sirolimus coated balloon

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel-eluting balloon (SeQuent Please Neo)
Description: PCI treatment with DCB, in particular paclitaxel coated balloon
Study: NCT05853861

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER is an evidence based early intervention that focuses on the core social communication and engagement skills of young children that are important to improvements in communication and language.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Babble Bootcamp
Description: Babble Bootcamp is a new intervention focusing on the speech-motor system and aims to improve babbling and early word use in infants known to be at risk for language delay.
Study: NCT06215573

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: 5mg melatonin supplement, once daily, from Ritual BioSeries

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Placebo supplement, once daily, from Ritual BioSeries
Study: NCT06510543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goal-directed EN therapy
Description: The participants will be administered a supervised goal-directed nutritional therapy. The enteral nutrition (EN) regimens include homemade meals with or without ORAL IMPACT® according to the daily goal.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Conventional EN therapy
Description: The participants will be administered the conventional nutritional therapy according to the Chinese expert consensus on perioperative nutritional support in enhanced recovery after surgery (2019 edition).
Study: NCT06198829

Intervention type: OTHER
Intervention: Physical examination tests and surveys
Description: Patients'hip joint range of motion range of motion, pain levels, pressure-pain threshold levels, kinesiophobia levels, and hip dysfunction levels will be measured, and the alpha angle will be evaluated on hip radiographs.
Study: NCT06129916

Intervention type: DRUG
Intervention: long-acting depot buprenorphine (LADB)
Description: The intervention will measure patient-centered outcomes in people initiating LADB among a cohort of opioid-dependent PWID across sites in the seven project LMIC. Study participants will be enrolled from selected clinics that deliver routine opioid agonist maintenance treatment to PWID. The intervention will 1) Compare characteristics at baseline of those service clients who do and do not initiate LADB in relation to demographic characteristics, history of drug use, and outcomes; 2) Measure side effects and adverse events among those initiating LADB; and 3) Where appropriate, assess changes in outcomes between time of LADB initiation and 48 week follow-up, including HCV and HIV testing and treatment, quality of life, employment opportunities, and service preferences.
Study: NCT04818840

Intervention type: DEVICE
Intervention: Resurfaced Patella
Description: JOURNEY II CR Total Knee System was used for Total Knee replacement

Intervention type: PROCEDURE
Intervention: Un-resurfaced Patella
Description: JOURNEY II CR Total Knee System was used for Total Knee replacement
Study: NCT05904834

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flexibility training
Description: Each session consisted of three or four exercises, of which three were static stretches and if there was a fourth, it was dynamic. The duration of each exercise was 20 seconds with 15 seconds rest between sets and 30 seconds rest between exercises.
Study: NCT04047836

Intervention type: OTHER
Group type: OTHER
Intervention: Low Nicotine E-Liquid
Description: Participants will vape e-liquid with nicotine concentration of 3 mg/ml.

Intervention type: OTHER
Group type: OTHER
Intervention: Medium or High Nicotine E-Liquid
Description: Participants will vape either e-liquid with nicotine concentration of 18 mg/ml or a JUUL device with JUUL pod of 59 mg/ml nicotine e-liquid.
Study: NCT04782297

Intervention type: DEVICE
Intervention: Long term hemodialysis catheter
Description: There will be no interventions in this study. Strictly observational.

Intervention type: DEVICE
Intervention: Long term hemodialysis catheter
Description: There will be no interventions in this study. Strictly observational.
Study: NCT06401473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ipsilateral Scratch Task
Description: Patients scratch the skin within the relevant cervical dermatome, ipsilateral to the injection site

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Motor Distraction Task
Description: Patients scratch the skin of the shoulder/neck contralateral to the injection site
Study: NCT06575244

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based sailing
Description: A nature-based intervention, the Resilience AND Well-being Building through Oceanic Nautical Empowerment (RAWBONE) sailing program is validated by an expert panel including professionals from various fields, such as a registered nurse, educators specializing in NBIs, occupational therapists, physiotherapists, clinical psychologists, speech therapists, academics specializing in children's well-being, pediatricians, and qualified sailing instructors, delivered in a group of 6 participants, incorporating experiential learning and positive reinforcement, with the aid of materials including dinghies with Universal design, safety boats, buoys, buoyancy aids, supplementing with a waterproof sailing booklet and social skills booklet. The intervention is developed and facilitated by a registered nurse (principal investigator).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: A self-developed social skill booklet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care
Description: A self-developed social skill booklet
Study: NCT06520592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: With AR guided CPAP therapy
Description: Participants will received AR training course to utilize the AR guided CPAP therapy
Study: NCT06576024

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses of HAV
Description: Participants will receive two doses of HAV with a 6-month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses of HAV
Description: Participants will receive two doses of HAV with a 6-month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 doses of HAV
Description: Participants will receive two doses of HAV with a 6-month interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: At least one dose of HAV
Description: Participants will receive the first dose of HAV and will receive the second dose with a 6 -month interval voluntarily.
Study: NCT05184504

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study: NCT06574841

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction training
Description: BFR training done 3 sessions per week, each session includes low intensity of 20% to 30% of 1RM, 3 sets of 15 to 30 reps with a 30sec resting period done for 6 weeks.Moreover, nerve and tendon-gliding exercises consists of 10 reps with a 5-second hold, 3-5 times done daily for 5 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction training
Description: BFR training done 3 sessions per week, each session includes low intensity of 20% to 30% of 1RM, 3 sets of 15 to 30 reps with a 30sec resting period done for 6 weeks.Moreover, nerve and tendon-gliding exercises consists of 10 reps with a 5-second hold, 3-5 times done daily for 5 weeks.
Study: NCT06575426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPF-310
Description: Dose(Part1): 6,000 islet equivalents (IEQ)/kg or 12,000 islet equivalents (IEQ)/kg~Dose(Part2): Recommended Phase II Dose(RP2D), which will be determined based on the data of Part1~* In Part1, three subjects will be enrolled into the first dosing cohort (Cohort 1: 6,000 IEQ/kg) and they will undergo safety monitoring. Three subjects in Cohort 2 will be dosed with 12,000 IEQ/kg and will undergo safety monitoring.~* In Part2, 7 subjects will be enrolled into the Part 2 dose-expansion part.
Study: NCT05833399

Intervention type: DRUG
Intervention: Quetiapine, olanzapine, mirtazapine, carbamazepine, sertraline, amitriptyline, chlorpromazine and risperidone
Description: Medications are prescribed orally for outpatient or inpatient treatment of addicted patients.
Study: NCT06353685

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Continuous, hyperfractionated, accelerated radiotherapy(CHART)
Description: high-risk CTV area (CTV1), 45Gy in total, fraction dose of 1.5Gy, twice a day, bioequivalent dose (BED) of 51.75Gy; Low-risk CTV area(CTV2), 39Gy in total , fraction dose of 1.3Gy, twice a day, BED of 44.07Gy; A total of 30 radiotherapy fraction were performed 10 times a week for 3 weeks.
Study: NCT05566470

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Central Neuromuscular Dysfunction, Shoulder Physical Functionality and Psychological Factors
Description: Each of the 2 groups will be evaluated in terms of functional level and psychological factors; American Shoulder and Elbow Surgeons evaluation form (ASES), Connor-Davidson Psychological Resilience Scale (CDPRS) and the Depression, Anxiety, Stress-21 Scale (DASS-21) will be used to evaluate these factors. Furthermore, the corticospinal excitability of the deltoid muscle will be assessed with Transcranial Magnetic Stimulation (TMS). Both deltoid muscles of the patient will be evaluated by saving motor evoked potentials signals that respond to TMS, and motor excitability will be compared between the affected arm and the unaffected arm. In addition, the control group will also be assessed in terms of functional level and psychological factors with TMS, ASES, DASS-21 and CPDRS.

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of Central Neuromuscular Dysfunction, Shoulder Physical Functionality and Psychological Factors
Description: Each of the 2 groups will be evaluated in terms of functional level and psychological factors; American Shoulder and Elbow Surgeons evaluation form (ASES), Connor-Davidson Psychological Resilience Scale (CDPRS) and the Depression, Anxiety, Stress-21 Scale (DASS-21) will be used to evaluate these factors. Furthermore, the corticospinal excitability of the deltoid muscle will be assessed with Transcranial Magnetic Stimulation (TMS). Both deltoid muscles of the patient will be evaluated by saving motor evoked potentials signals that respond to TMS, and motor excitability will be compared between the affected arm and the unaffected arm. In addition, the control group will also be assessed in terms of functional level and psychological factors with TMS, ASES, DASS-21 and CPDRS.
Study: NCT05577013

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping
Description: It will be applied by kinesiotape certified physiotherapist on tendons in the direction of extensor muscle to facilitate range of motion by stretching 50%. At first it will be applied on extensor pollicis longus and extensor pollicis brevis muscles of hand, extensor digitorum and extensor indicis of last 4 fingers of hand. Triceps brachii in arm and Supraspinatus and Infraspinatus muscles to stabilize the gelnohumeral joint

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor relearning program
Description: Stacking up blocks Stacking up polystyrene cups Folding piece of cloth Using cutlery Pouring water into glass Closing/opening lid of bottles turning the pages of books or newspaper writing on paper Squeezing of ball Coloring in different shapes
Study: NCT06291038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: • Experimental group: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks
Description: treatment with glutamine at a dose of 5g 3 times a day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: • Control group: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
Description: treatment with a protein powder (Protifar) (Placébo) 5g 3 times a day for 8 weeks.
Study: NCT06276868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalcilib+letrozole+HP treatment group
Description: All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
Study: NCT06246604

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound screening for lower limbs DVT
Description: Using a linear ultrasound probe (7.5-12 MHz) a compression ultrasound of the lower limbs is performed, from the hip to the ankle. The exam is completed by the use of Doppler.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care
Description: Ultrasound examination of lower limbs is performed according to clinical risk of DVT
Study: NCT06470165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Priority-matching correction technique in DLS
Description: For Type 1 global coronal malalignment (GCM), TL/L curve makes the primary contri- bution on C7PL shifting. First, inserting pedicle screws bilaterally. Second, aggressively decreasing the magnitude of TL/L curve. Third, moderately leveling L4 endplate to pull the fusion segments to the middle line with hand pressure on the convexity of TL/L curve. If the correctability of the key curve was limited, the correction of the minor curve would be con- vergent.~For Type 2 GCM, LS curve makes the primary contribution on C7PL shifting. First, releasing LS curve from the concave side using facetectomy after screws inserted. Second, performing L4-5 or L5-S1 trans- foraminal lumbar interbody fusion (TLIF) from the con- vexity of the fractional curve, with cages inserted at the concave side to assist deformity correction. Third, compressing the convexity of LS to horizontalize L4 endplate, followed by moderate manipulative reduction of TL/L curve to adjust intraoperative coronal balance.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Traditional correction technique in DLS
Description: In concave coronal malalignment (CM), the correction of the main curve improves the CM, thus we can talk about convergent corrective objectives. The ability to correct the CM depends on the correctability of the main curve. The need of three-column osteotomies in order to obtain correction of CM depends on the location and flexibility of the main curve.~The correction of convex CM depends on the correction of the lumbosacral curve. The correction strategy will depend on many factors including the driver of the deformity, which should always be fused, but also the degeneration and stiffness of the compensatory curve which can lead to more extended fusion. The need of three-column osteotomies depends mainly on the stiffness of the lumbosacral curve.
Study: NCT05777265

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Circuit Training
Description: CT will be applied to the participants, taking into account the recommendations of the American College of Sports Medicine (ACSM), 3 days a week, an average of 40 minutes a day, for a total of 16 weeks. Warm-up and cool-down protocols will be applied before and after each CT, and each exercise will be performed as 15 repetitions and an average of 40 seconds of rest will be given between exercises. Also, the intensity of CT will be determined according to the Borg scale (between 11 and 14). CT will include 'mini squat', 'step up', 'sit ups', 'reverse sit ups', 'leg press', 'leg curl', 'leg extension', 'crunches', 'lunge', 'prone bridge', and 'side bridge' exercises.
Study: NCT05322564

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized opiate prescription
Description: The standardized prescription will include a single opiate, with a fixed dose and number of tablets. It will also include non-opiate adjuncts commonly prescribed at our institution, namely acetaminophen and an anti-inflammatory medication.
Study: NCT04997668

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SOLTIVE Thulium Fiber Laser
Description: Patients randomized to Arm A will undergo surgery to remove their kidney stone with FDA approved SOLTIVE Thulium Fiber Laser.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ho:YAG Laser
Description: Patients randomized to Arm B will undergo surgery to remove their kidney stone with FDA approved Ho:YAG laser.
Study: NCT06574971

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low intensity focused ultrasound using the NeurGear Zenbud
Description: The NeurGear Zenbud is a wearable earbud that delivers low intensity focused ultrasound to the auricular branch of the vagus nerve
Study: NCT05422378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP705
Description: STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: STP705
Description: STP705 composed of 2 siRNA targeting TGF-B1and COX-2 individually.
Study: NCT05925088

Intervention type: OTHER
Intervention: Focus group
Description: Participants will take part in a 1 hour focus group.

Intervention type: OTHER
Intervention: Focus group
Description: Participants will take part in a 1 hour focus group.